SAN DIEGO
Zogenix Inc. said Wednesday it received a new patent on its needle-less migraine treatment Sumavel DosePro.The patents expires in April 2025, which is eight years later than any of the other patents supporting Sumavel Dose Pro. Sumavel DosePro delivers a dose of the migraine drug sumatriptan beneath the skin without a needle. In the U.S., Zogenix co-promotes the drug with Astellas Pharma.
Read the rest of the article here.
No comments:
Post a Comment